{"__slider":[],"__countdown":[{"gallery":[],"secstyle":"","imageObject":"202311150940731107.png","imageSecond":false,"sectionbg":"","background_image":false,"id":137,"title":"Second Investigational Study Of our COV19\u2122 Replicates Results Of Earlier Trial In Eliminating COVID-19 Symptoms","subtitle":"","social":{"instagram":"","facebook":"","linkedin":"","youtube":""},"content":"\u003Cdiv class=\"_content\"\u003E\u003Ch6 style=\"text-align:justify\"\u003E\u003Cstrong\u003ENews Report by\u00a0Beth Senko,\u00a0CFA (Senior Analyst)\u00a0\u003C\/strong\u003E\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EIn March 2020, Regencell\u2019s strategic partner and TCM practitioner, Mr. Sik-Kee Au, modified his proprietary cold and flu TCM formula for use in COVID-19 patients. The TCM practitioner subsequently treated 9 voluntary COVID-19 patients in the United States and patients showed improvements after an average of five days. Based on these promising results, Regencell formed a joint venture with Honor Epic Enterprises Limited in September 2021 to conduct further tests and commercialize Regencell\u2019s COVID-19 treatment in ASEAN countries.\u003C\/p\u003E\r\n\r\n\u003Ch6 style=\"text-align:justify\"\u003E\u003Cstrong\u003EEARTH Efficacy Trials (EARTH-A Trial and EARTH-B Trial)\u003C\/strong\u003E\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EFrom March 2020 to August 2021, Regencell set up protocols and procedures to conduct the Evaluation and Assessment of RGC-COV19\u003Csup\u003ETM\u003C\/sup\u003E\u00a0TCM through a Holistic approach (EARTH) efficacy trial in Malaysia and the United States. The first\u00a0\u003Ca href=\"https:\/\/scr.zacks.com\/news\/news-details\/2022\/RGC-Regencell-Bioscience---Investigational-Liquid-Formula-RGC-COV19-shows-promise-in-eliminating-COVID-19-symptoms\/default.aspx\"\u003EEARTH\u003C\/a\u003E\u00a0efficacy trial (\u003Cstrong\u003EEARTH-A Trial\u003C\/strong\u003E), was a non-blinded trial of 37 subjects to study the efficacy of Regencell\u2019s TCM formula for COVID-19 (RCG-COV19\u003Csup\u003ETM\u003C\/sup\u003E) over a six-day treatment period. In the EARTH-A Trial, of the 37 subjects, 36 patients (97.3%) had all mild-to-moderate symptoms eliminated (except for Sensory Dysfunction or occasional cough) within six days.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EAn additional efficacy trial (EARTH-B Trial) was conducted from January 30 to March 31, 2022 to corroborate EARTH-A\u2019s results. The EARTH-B Trial followed the same design as the EARTH-A Trial, on a larger group of subjects. During the EARTH-B Trial, the Omicron variant accounted for 80% of COVID-19 cases in Malaysia. The EARTH-A Trial was conducted when Delta was the dominant variant.\u003C\/p\u003E\u003C\/div\u003E","blurb":"","link":"","linktitle":"","links":[],"alink":"","buttons":"","imageObjectTitle":"","imageObjectSrc":"management.file\/img\/202311150940731107.png","imageObjectImg":"\u003Cdiv class=\"_imgobj p-r\"\u003E\u003Cimg src=\"management.file\/img\/202311150940731107.png\" \/\u003E\u003C\/div\u003E","imageObjectBg":"background-image: url(management.file\/img\/202311150940731107.png);","imageSecondTitle":"","imageSecondSrc":"","imageSecondImg":"","imageSecondBg":"","ittlsec":"\u003Cdiv class=\"_ittl\"\u003E\u003Cdiv class=\"ttldecor- ttldecor-top\"\u003E\u003C\/div\u003E\u003Ch4 class=\"h4\"\u003ESecond Investigational Study Of our COV19\u2122 Replicates Results Of Earlier Trial In Eliminating COVID-19 Symptoms\u003C\/h4\u003E\u003Cdiv class=\"ttldecor- ttldecor-btm\"\u003E\u003C\/div\u003E\u003C\/div\u003E","h":"\u003Cdiv class=\"_ittl\"\u003E\u003Cdiv class=\"ttldecor- ttldecor-top\"\u003E\u003C\/div\u003E\u003Ch4 class=\"h4\"\u003ESecond Investigational Study Of our COV19\u2122 Replicates Results Of Earlier Trial In Eliminating COVID-19 Symptoms\u003C\/h4\u003E\u003Cdiv class=\"ttldecor- ttldecor-btm\"\u003E\u003C\/div\u003E\u003C\/div\u003E","maintitle":"","sectitle":"\u003Cdiv class=\"_secttlbx\"\u003E\n \n \u003Cdiv class=\"ttldecor- ttldecor-top\"\u003E\u003C\/div\u003E\u003Cdiv class=\"ttldecor- ttldecor-btm\"\u003E\u003C\/div\u003E\n \n \u003Cdiv class=\"_ttlcontent _content\"\u003E\u003Ch6 style=\"text-align:justify\"\u003E\u003Cstrong\u003ENews Report by\u00a0Beth Senko,\u00a0CFA (Senior Analyst)\u00a0\u003C\/strong\u003E\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EIn March 2020, Regencell\u2019s strategic partner and TCM practitioner, Mr. Sik-Kee Au, modified his proprietary cold and flu TCM formula for use in COVID-19 patients. The TCM practitioner subsequently treated 9 voluntary COVID-19 patients in the United States and patients showed improvements after an average of five days. Based on these promising results, Regencell formed a joint venture with Honor Epic Enterprises Limited in September 2021 to conduct further tests and commercialize Regencell\u2019s COVID-19 treatment in ASEAN countries.\u003C\/p\u003E\r\n\r\n\u003Ch6 style=\"text-align:justify\"\u003E\u003Cstrong\u003EEARTH Efficacy Trials (EARTH-A Trial and EARTH-B Trial)\u003C\/strong\u003E\u003C\/h6\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EFrom March 2020 to August 2021, Regencell set up protocols and procedures to conduct the Evaluation and Assessment of RGC-COV19\u003Csup\u003ETM\u003C\/sup\u003E\u00a0TCM through a Holistic approach (EARTH) efficacy trial in Malaysia and the United States. The first\u00a0\u003Ca href=\"https:\/\/scr.zacks.com\/news\/news-details\/2022\/RGC-Regencell-Bioscience---Investigational-Liquid-Formula-RGC-COV19-shows-promise-in-eliminating-COVID-19-symptoms\/default.aspx\"\u003EEARTH\u003C\/a\u003E\u00a0efficacy trial (\u003Cstrong\u003EEARTH-A Trial\u003C\/strong\u003E), was a non-blinded trial of 37 subjects to study the efficacy of Regencell\u2019s TCM formula for COVID-19 (RCG-COV19\u003Csup\u003ETM\u003C\/sup\u003E) over a six-day treatment period. In the EARTH-A Trial, of the 37 subjects, 36 patients (97.3%) had all mild-to-moderate symptoms eliminated (except for Sensory Dysfunction or occasional cough) within six days.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EAn additional efficacy trial (EARTH-B Trial) was conducted from January 30 to March 31, 2022 to corroborate EARTH-A\u2019s results. The EARTH-B Trial followed the same design as the EARTH-A Trial, on a larger group of subjects. During the EARTH-B Trial, the Omicron variant accounted for 80% of COVID-19 cases in Malaysia. The EARTH-A Trial was conducted when Delta was the dominant variant.\u003C\/p\u003E\r\n\u003C\/div\u003E\n \u003C\/div\u003E","iframe":"","date":"","documentSrc":"","document":"","documentTitle":"","videoSrc":"","video":"","videoTitle":""}],"__step":[],"__otherstep":[],"__textslide":[],"__message1":[{"gallery":[],"secstyle":"","imageObject":"202311153871807002.png","imageSecond":"","sectionbg":"","background_image":false,"id":139,"title":"","subtitle":"","social":{"instagram":"","facebook":"","linkedin":"","youtube":""},"content":"\u003Cdiv class=\"_content\"\u003E\u003Cp style=\"text-align:justify\"\u003E51 subjects in Malaysia, aged 11 to 75, were enrolled for the EARTH-B Trial. They were of different races, ethnicity and socioeconomic background. All subjects showed onset of symptoms within five days of treatment initiation and laboratory-confirmed diagnosis of COVID-19 within three days to the start of treatment. Subjects with a confirmed diagnosis of COVID-19 but who were asymptomatic, were excluded from the study.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EIn the EARTH-B Trial, 50 subjects were fully-vaccinated and the one unvaccinated subject was 11 years old. Subjects who were vaccinated either received Pfizer-BioNTech, AstraZeneca or Sinovac-CoronaVac, the top three vaccines distributed in Malaysia.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EEach subject was first given two doses of Regencell\u2019s formula (two days of treatment) and were followed for a maximum of six days. Subjects took a reverse transcription-polymerase chain reaction test (RT-PCR test) for COVID-19 every two days. The COVID-19 treatment ended upon patients receiving a negative RT-PCR test or when their symptoms were gone (except for loss or reduce of sense of smell and\/or taste (Sensory Dysfunction) or occasional cough), at the end of the six-day study period.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ETo assess the efficacy and time to symptom improvement\/resolution, patients recorded their symptoms daily on a three-point scale ranging from mild to severe. Patients were asked to log specific symptoms such as fever (including hot flashes or chills), upper respiratory issues (cough, sore throat, runny nose), lower respiratory issues (shortness of breath, chest pain or pressure), muscle aches, nausea, abdominal discomfort, and drowsiness, and to identify any other symptoms they were experiencing. The largest number of different symptoms reported by the enrolled patients was 16 and the average number of different symptoms reported was approximately 7.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ENone of the trial subjects was hospitalized and there was no death. The efficacy of RGC-COV19\u003Csup\u003ETM\u003C\/sup\u003E\u00a0was not affected by timing of symptom onset or underlying risk factor. Results were consistent across all ages, gender, races and ethnicity demographic among subjects.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u003Cstrong\u003E\u003Cem\u003ESymptoms elimination\u003C\/em\u003E\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EOf the 51 subjects, 48 patients (94.1%) had all mild-to-moderate symptoms eliminated (except for Sensory Dysfunction or occasional cough) within six days. 46 of 51 patients (90.2%) reported elimination of one or more symptoms after one day of treatment, which is considerably better than the 83.8% response reported in the EARTH-A Trial. On average, subject reported elimination of all symptoms (except Sensory Dysfunction and occasional cough) 3.6 days after starting treatment.\u003C\/p\u003E\u003C\/div\u003E","blurb":"","link":"","linktitle":"","links":[],"alink":"","buttons":"","imageObjectTitle":"","imageObjectSrc":"management.file\/img\/202311153871807002.png","imageObjectImg":"\u003Cdiv class=\"_imgobj p-r\"\u003E\u003Cimg src=\"management.file\/img\/202311153871807002.png\" \/\u003E\u003C\/div\u003E","imageObjectBg":"background-image: url(management.file\/img\/202311153871807002.png);","imageSecondTitle":"","imageSecondSrc":"","imageSecondImg":"","imageSecondBg":"","ittlsec":"","h":"","maintitle":"","sectitle":"\u003Cdiv class=\"_secttlbx\"\u003E\n \n \u003Cdiv class=\"ttldecor- ttldecor-top\"\u003E\u003C\/div\u003E\u003Cdiv class=\"ttldecor- ttldecor-btm\"\u003E\u003C\/div\u003E\n \n \u003Cdiv class=\"_ttlcontent _content\"\u003E\u003Cp style=\"text-align:justify\"\u003E51 subjects in Malaysia, aged 11 to 75, were enrolled for the EARTH-B Trial. They were of different races, ethnicity and socioeconomic background. All subjects showed onset of symptoms within five days of treatment initiation and laboratory-confirmed diagnosis of COVID-19 within three days to the start of treatment. Subjects with a confirmed diagnosis of COVID-19 but who were asymptomatic, were excluded from the study.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EIn the EARTH-B Trial, 50 subjects were fully-vaccinated and the one unvaccinated subject was 11 years old. Subjects who were vaccinated either received Pfizer-BioNTech, AstraZeneca or Sinovac-CoronaVac, the top three vaccines distributed in Malaysia.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EEach subject was first given two doses of Regencell\u2019s formula (two days of treatment) and were followed for a maximum of six days. Subjects took a reverse transcription-polymerase chain reaction test (RT-PCR test) for COVID-19 every two days. The COVID-19 treatment ended upon patients receiving a negative RT-PCR test or when their symptoms were gone (except for loss or reduce of sense of smell and\/or taste (Sensory Dysfunction) or occasional cough), at the end of the six-day study period.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ETo assess the efficacy and time to symptom improvement\/resolution, patients recorded their symptoms daily on a three-point scale ranging from mild to severe. Patients were asked to log specific symptoms such as fever (including hot flashes or chills), upper respiratory issues (cough, sore throat, runny nose), lower respiratory issues (shortness of breath, chest pain or pressure), muscle aches, nausea, abdominal discomfort, and drowsiness, and to identify any other symptoms they were experiencing. The largest number of different symptoms reported by the enrolled patients was 16 and the average number of different symptoms reported was approximately 7.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ENone of the trial subjects was hospitalized and there was no death. The efficacy of RGC-COV19\u003Csup\u003ETM\u003C\/sup\u003E\u00a0was not affected by timing of symptom onset or underlying risk factor. Results were consistent across all ages, gender, races and ethnicity demographic among subjects.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u003Cstrong\u003E\u003Cem\u003ESymptoms elimination\u003C\/em\u003E\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003EOf the 51 subjects, 48 patients (94.1%) had all mild-to-moderate symptoms eliminated (except for Sensory Dysfunction or occasional cough) within six days. 46 of 51 patients (90.2%) reported elimination of one or more symptoms after one day of treatment, which is considerably better than the 83.8% response reported in the EARTH-A Trial. On average, subject reported elimination of all symptoms (except Sensory Dysfunction and occasional cough) 3.6 days after starting treatment.\u003C\/p\u003E\r\n\u003C\/div\u003E\n \u003C\/div\u003E","iframe":"","date":"","documentSrc":"","document":"","documentTitle":"","videoSrc":"","video":"","videoTitle":""}],"__message2":[{"gallery":[],"secstyle":"","imageObject":"202311156077010333.png","imageSecond":false,"sectionbg":"","background_image":false,"id":140,"title":"","subtitle":"","social":{"instagram":"","facebook":"","linkedin":"","youtube":""},"content":"\u003Cdiv class=\"_content\"\u003E\u003Cp style=\"text-align:justify\"\u003E\u003Cstrong\u003E\u003Cem\u003EClearing the virus \u2013 negative RT-PCR test\u003C\/em\u003E\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ESubjects took RT-PCR tests every other day during the study. In Malaysia, the threshold for \u2018not detected\u2019 is above 40, meaning a CT value of 40 or lesser means a person is COVID-19 positive while a CT value of more than 40 means a person tested negative for COVID-19. Of the 51 subjects in the study, 23.5% (n=12) tested negative for COVID-19 by the end of the study. The remaining 36 subjects who reported all symptoms eliminated (excluding Sensory Dysfunction and\/or occasional cough) before the end of the study (averaging recovery period of 3.4 days) were not further tested for COVID-19.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u003Cimg alt=\"\" src=\"management.file\/img\/202311157338910070.png\" style=\"height:524px; width:830px\" \/\u003E\u003Cbr \/\u003E\r\n\u003Cbr \/\u003E\r\n\u003Cstrong\u003E\u003Cem\u003ESensory dysfunction and breathing difficulty\u003C\/em\u003E\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003ESensory dysfunction (loss or reduce of sense of smell or taste) appears to linger beyond the six-day study period for many subjects. Prior to receiving treatment, 17 of 51 subjects reported sensory dysfunction. 11 of the subjects regained their sense of smell and\/or taste at the end of the six-day study, while the other six reported improvement.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EPrior to treatment, 15 patients reported experiencing a combination of dyspnea (difficulty in breathing) and persistent chest pain. 10 of these 15 patients no longer experienced difficulty in breathing and\/or persistent chest pain after 1 full dose of RGC-COV19\u003Csup\u003ETM\u003C\/sup\u003E.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003ERegencell\u2019s COVID-19 formula\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003ERGC-COV19\u003Csup\u003ETM\u003C\/sup\u003E\u00a0is a natural formula designed by the TCM Practitioner according to the TCM Practitioner\u2019s brain theory known as \u201cSik-Kee Au TCM Brain Theory\u003Csup\u003E\u00ae\u003C\/sup\u003E\u201d.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EAccording to the brain theory, brain functions depend on oxygen level required for the brain to perform normal cognitive functions. For optimal brain performance, the heart needs to function normally to deliver sufficient oxygen to the brain. When the heart is weakened, the heart\u2019s ability to deliver enough blood to circulate oxygen throughout the body is impaired. When this happens, brain functions are suppressed, resulting in a person experiencing fatigue, nausea, disorientation and reduced immune response.\u003C\/p\u003E\r\n\r\n\u003Cp\u003ERGC-COV19\u003Csup\u003ETM\u003C\/sup\u003E\u00a0is designed by the TCM Practitioner to strengthen the heart\u2019s functions. According to the brain theory, when the heart is strengthened, it increases blood flow and delivers more oxygen to the brain, resulting in reduced blood clots and restored brain functions.\u003C\/p\u003E\r\n\r\n\u003Cp\u003ERegardless of the COVID-19 variant, the lungs and heart are where the coronavirus does much of its damage, and such infection can set off an inflammatory immune response that ravages infected and uninfected cells alike, leading to tissue scarring and oxygen deprivation which will in turn reduce optimal brain function. RGC-COV19\u003Csup\u003ETM\u003C\/sup\u003E\u00a0is a natural formula designed by the TCM Practitioner according to the TCM Practitioner\u2019s brain theory known as \u201cSik-Kee Au TCM Brain Theory\u00ae\u201d.\u003C\/p\u003E\r\n\r\n\u003Cp\u003ERGC-COV19\u003Csup\u003ETM\u003C\/sup\u003E\u00a0has been formulated to generate more responsive cognitive function which in turn, stimulates the body\u2019s own healing mechanism to reduce COVID-19 symptoms. RGC\u2019s formula and the body\u2019s own response work together to:\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 reduce and clear the mucus and phlegm from the upper respiratory system;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 dispel exterior viral pathogen via heavy sweats, urine and excrement;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 clear endogenous and liver heat;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 detox the liver, and\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 improve circulation.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003E\u003Cem\u003EUpcoming results in follow-on study of ASD\/ADHD treatment formula\u003C\/em\u003E\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003ERegencell Bioscience is expected to report results of a follow-on study for its ASD\/ADHD treatment. Currently, the Company is working towards the production of an effective standardized formula for commercialization purposes.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EThe formula is based on the \u201cSik-Kee Au TCM Brain Theory\u00ae\u201d that ASD and ADHD stem from inadequate blood flow and creation of neurotransmitters in the developing brain. As we discussed earlier, this hypothesis is complementary to the western medicine view that ASD and ADHD are present at birth and arise from developmental differences in brain function.\u003C\/p\u003E\r\n\r\n\u003Cp\u003ERegencell Bioscience\u2019s first clinical trial was designed to establish benchmarks for treatment, dosing, adverse effects (AEs) and measuring patients\u2019 response in a systematic and repeatable way, while evaluating the effectiveness of a customized TCM formula.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EAs a customized formula is designed to suit each patient\u2019s symptoms, the ability for it to be produced in large quantities is limited as compared to a standardized formula. Regencell is currently evaluating and assessing the effectiveness of a standardized TCM formula in reducing ADHD and ASD symptoms in children through a holistic approach within 3 months of treatment, in its second efficacy trial.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003EPath to registration and commercialization\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003ERegencell Bioscience has a four-year timeframe to commercialize its standardized formulations and gain proprietary Chinese medicine (pCm) registration in Hong Kong. The Company has a number of tasks ahead:\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 Completing its second clinical trial for ASD\/ADHD and COVID, and evaluating results.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 Conducting additional clinical trials to support its proprietary formulae in ASD\/ADHD and other applications.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 Obtaining patents and other forms of IP protection in Hong Kong and other markets.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 Establishing manufacturing capability and supply chain that will meet registration requirements.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 Assembling and filing documentation for pCm approval.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 Build out its marketing and distribution strategy and infrastructure.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EWe believe that an emphasis on conducting well-designed clinical trials that measure outcomes based on well-established assessment instruments, will provide Regencell Bioscience with a competitive advantage in terms of expertise and credibility in an industry that is moving towards higher standards for efficacy, safety and quality. While there is still much work to do, in our view, Regencell Bioscience is taking a thoughtful, systematic approach to developing its TCM formulae.\u003C\/p\u003E\r\n\r\n\u003Cp\u003ESource:\u00a0\u003Ca href=\"https:\/\/scr.zacks.com\/news\/news-details\/2022\/RGC-Second-investigational-study-of-RGC-COV19-replicates-results-of-earlier-trial-in-eliminating-COVID-19-symptoms.-\/default.aspx\"\u003EZacks Small Cap Research\u003C\/a\u003E\u003C\/p\u003E\u003C\/div\u003E","blurb":"","link":"","linktitle":"","links":[],"alink":"","buttons":"","imageObjectTitle":"","imageObjectSrc":"management.file\/img\/202311156077010333.png","imageObjectImg":"\u003Cdiv class=\"_imgobj p-r\"\u003E\u003Cimg src=\"management.file\/img\/202311156077010333.png\" \/\u003E\u003C\/div\u003E","imageObjectBg":"background-image: url(management.file\/img\/202311156077010333.png);","imageSecondTitle":"","imageSecondSrc":"","imageSecondImg":"","imageSecondBg":"","ittlsec":"","h":"","maintitle":"","sectitle":"\u003Cdiv class=\"_secttlbx\"\u003E\n \n \u003Cdiv class=\"ttldecor- ttldecor-top\"\u003E\u003C\/div\u003E\u003Cdiv class=\"ttldecor- ttldecor-btm\"\u003E\u003C\/div\u003E\n \n \u003Cdiv class=\"_ttlcontent _content\"\u003E\u003Cp style=\"text-align:justify\"\u003E\u003Cstrong\u003E\u003Cem\u003EClearing the virus \u2013 negative RT-PCR test\u003C\/em\u003E\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003ESubjects took RT-PCR tests every other day during the study. In Malaysia, the threshold for \u2018not detected\u2019 is above 40, meaning a CT value of 40 or lesser means a person is COVID-19 positive while a CT value of more than 40 means a person tested negative for COVID-19. Of the 51 subjects in the study, 23.5% (n=12) tested negative for COVID-19 by the end of the study. The remaining 36 subjects who reported all symptoms eliminated (excluding Sensory Dysfunction and\/or occasional cough) before the end of the study (averaging recovery period of 3.4 days) were not further tested for COVID-19.\u003C\/p\u003E\r\n\r\n\u003Cp style=\"text-align:justify\"\u003E\u003Cimg alt=\"\" src=\"management.file\/img\/202311157338910070.png\" style=\"height:524px; width:830px\" \/\u003E\u003Cbr \/\u003E\r\n\u003Cbr \/\u003E\r\n\u003Cstrong\u003E\u003Cem\u003ESensory dysfunction and breathing difficulty\u003C\/em\u003E\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003ESensory dysfunction (loss or reduce of sense of smell or taste) appears to linger beyond the six-day study period for many subjects. Prior to receiving treatment, 17 of 51 subjects reported sensory dysfunction. 11 of the subjects regained their sense of smell and\/or taste at the end of the six-day study, while the other six reported improvement.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EPrior to treatment, 15 patients reported experiencing a combination of dyspnea (difficulty in breathing) and persistent chest pain. 10 of these 15 patients no longer experienced difficulty in breathing and\/or persistent chest pain after 1 full dose of RGC-COV19\u003Csup\u003ETM\u003C\/sup\u003E.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003ERegencell\u2019s COVID-19 formula\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003ERGC-COV19\u003Csup\u003ETM\u003C\/sup\u003E\u00a0is a natural formula designed by the TCM Practitioner according to the TCM Practitioner\u2019s brain theory known as \u201cSik-Kee Au TCM Brain Theory\u003Csup\u003E\u00ae\u003C\/sup\u003E\u201d.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EAccording to the brain theory, brain functions depend on oxygen level required for the brain to perform normal cognitive functions. For optimal brain performance, the heart needs to function normally to deliver sufficient oxygen to the brain. When the heart is weakened, the heart\u2019s ability to deliver enough blood to circulate oxygen throughout the body is impaired. When this happens, brain functions are suppressed, resulting in a person experiencing fatigue, nausea, disorientation and reduced immune response.\u003C\/p\u003E\r\n\r\n\u003Cp\u003ERGC-COV19\u003Csup\u003ETM\u003C\/sup\u003E\u00a0is designed by the TCM Practitioner to strengthen the heart\u2019s functions. According to the brain theory, when the heart is strengthened, it increases blood flow and delivers more oxygen to the brain, resulting in reduced blood clots and restored brain functions.\u003C\/p\u003E\r\n\r\n\u003Cp\u003ERegardless of the COVID-19 variant, the lungs and heart are where the coronavirus does much of its damage, and such infection can set off an inflammatory immune response that ravages infected and uninfected cells alike, leading to tissue scarring and oxygen deprivation which will in turn reduce optimal brain function. RGC-COV19\u003Csup\u003ETM\u003C\/sup\u003E\u00a0is a natural formula designed by the TCM Practitioner according to the TCM Practitioner\u2019s brain theory known as \u201cSik-Kee Au TCM Brain Theory\u00ae\u201d.\u003C\/p\u003E\r\n\r\n\u003Cp\u003ERGC-COV19\u003Csup\u003ETM\u003C\/sup\u003E\u00a0has been formulated to generate more responsive cognitive function which in turn, stimulates the body\u2019s own healing mechanism to reduce COVID-19 symptoms. RGC\u2019s formula and the body\u2019s own response work together to:\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 reduce and clear the mucus and phlegm from the upper respiratory system;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 dispel exterior viral pathogen via heavy sweats, urine and excrement;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 clear endogenous and liver heat;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 detox the liver, and\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 improve circulation.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003E\u003Cem\u003EUpcoming results in follow-on study of ASD\/ADHD treatment formula\u003C\/em\u003E\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003ERegencell Bioscience is expected to report results of a follow-on study for its ASD\/ADHD treatment. Currently, the Company is working towards the production of an effective standardized formula for commercialization purposes.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EThe formula is based on the \u201cSik-Kee Au TCM Brain Theory\u00ae\u201d that ASD and ADHD stem from inadequate blood flow and creation of neurotransmitters in the developing brain. As we discussed earlier, this hypothesis is complementary to the western medicine view that ASD and ADHD are present at birth and arise from developmental differences in brain function.\u003C\/p\u003E\r\n\r\n\u003Cp\u003ERegencell Bioscience\u2019s first clinical trial was designed to establish benchmarks for treatment, dosing, adverse effects (AEs) and measuring patients\u2019 response in a systematic and repeatable way, while evaluating the effectiveness of a customized TCM formula.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EAs a customized formula is designed to suit each patient\u2019s symptoms, the ability for it to be produced in large quantities is limited as compared to a standardized formula. Regencell is currently evaluating and assessing the effectiveness of a standardized TCM formula in reducing ADHD and ASD symptoms in children through a holistic approach within 3 months of treatment, in its second efficacy trial.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003EPath to registration and commercialization\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003ERegencell Bioscience has a four-year timeframe to commercialize its standardized formulations and gain proprietary Chinese medicine (pCm) registration in Hong Kong. The Company has a number of tasks ahead:\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 Completing its second clinical trial for ASD\/ADHD and COVID, and evaluating results.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 Conducting additional clinical trials to support its proprietary formulae in ASD\/ADHD and other applications.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 Obtaining patents and other forms of IP protection in Hong Kong and other markets.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 Establishing manufacturing capability and supply chain that will meet registration requirements.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 Assembling and filing documentation for pCm approval.\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u2022 Build out its marketing and distribution strategy and infrastructure.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EWe believe that an emphasis on conducting well-designed clinical trials that measure outcomes based on well-established assessment instruments, will provide Regencell Bioscience with a competitive advantage in terms of expertise and credibility in an industry that is moving towards higher standards for efficacy, safety and quality. While there is still much work to do, in our view, Regencell Bioscience is taking a thoughtful, systematic approach to developing its TCM formulae.\u003C\/p\u003E\r\n\r\n\u003Cp\u003ESource:\u00a0\u003Ca href=\"https:\/\/scr.zacks.com\/news\/news-details\/2022\/RGC-Second-investigational-study-of-RGC-COV19-replicates-results-of-earlier-trial-in-eliminating-COVID-19-symptoms.-\/default.aspx\"\u003EZacks Small Cap Research\u003C\/a\u003E\u003C\/p\u003E\r\n\u003C\/div\u003E\n \u003C\/div\u003E","iframe":"","date":"","documentSrc":"","document":"","documentTitle":"","videoSrc":"","video":"","videoTitle":""}],"__gallery":[]}
